CA2103064A1 - Administration ciblee de genes codant pour des proteines immunogenes - Google Patents

Administration ciblee de genes codant pour des proteines immunogenes

Info

Publication number
CA2103064A1
CA2103064A1 CA 2103064 CA2103064A CA2103064A1 CA 2103064 A1 CA2103064 A1 CA 2103064A1 CA 2103064 CA2103064 CA 2103064 CA 2103064 A CA2103064 A CA 2103064A CA 2103064 A1 CA2103064 A1 CA 2103064A1
Authority
CA
Canada
Prior art keywords
polypeptide
gene
cell
molecular complex
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2103064
Other languages
English (en)
Inventor
George Y. Wu
George L. Spitalny
Mark A. Findeis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut
TargeTech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2103064A1 publication Critical patent/CA2103064A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CA 2103064 1991-05-14 1992-05-14 Administration ciblee de genes codant pour des proteines immunogenes Abandoned CA2103064A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69989191A 1991-05-14 1991-05-14
US699,891 1991-05-14

Publications (1)

Publication Number Publication Date
CA2103064A1 true CA2103064A1 (fr) 1992-11-15

Family

ID=24811356

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2103064 Abandoned CA2103064A1 (fr) 1991-05-14 1992-05-14 Administration ciblee de genes codant pour des proteines immunogenes

Country Status (9)

Country Link
EP (1) EP0584279B1 (fr)
JP (1) JPH06510524A (fr)
AT (1) ATE199647T1 (fr)
AU (1) AU668870B2 (fr)
CA (1) CA2103064A1 (fr)
DE (1) DE69231736T2 (fr)
DK (1) DK0584279T3 (fr)
ES (1) ES2154637T3 (fr)
WO (1) WO1992020316A2 (fr)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889169A (en) * 1991-05-16 1999-03-30 Cold Spring Harbor Laboratory Cell cycle regulatory protein p16 gene
US7550561B1 (en) 1991-05-16 2009-06-23 Cold Spring Harbor Laboratory p16INK4 polypeptides
AU735667B2 (en) * 1991-06-05 2001-07-12 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Targeted delivery of genes encoding secretory proteins
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5981273A (en) * 1991-09-30 1999-11-09 Boehringer Ingelheim Int'l. Gmbh Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US5922859A (en) * 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
US5656609A (en) * 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
US6211334B1 (en) 1992-10-16 2001-04-03 Cold Spring Harbor Cell-cycle regulatory proteins, and uses related thereto
US5962316A (en) * 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
AU688292B2 (en) * 1992-11-09 1998-03-12 United States Government as represented by the Department of Health and Human Services, The Targetable vector particles
US6043030A (en) * 1992-12-17 2000-03-28 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6331390B1 (en) 1992-12-17 2001-12-18 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
EP1770168A3 (fr) * 1993-01-26 2009-05-06 The Trustees of the University of Pennsylvania (a corporation of Pennsylvania) Compositions et procédés d'administration de matières génétiques
ATE302854T1 (de) * 1993-01-26 2005-09-15 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
US7001759B1 (en) 1993-01-26 2006-02-21 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US7691632B2 (en) 1993-11-18 2010-04-06 Cold Spring Harbor Laboratory Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression
US5728399A (en) * 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
WO1996021036A2 (fr) * 1994-12-30 1996-07-11 Chiron Viagene, Inc. Agents de concentration d'acide nucleique ayant une immunogenicite reduite
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5823453A (en) * 1995-11-14 1998-10-20 J & L Fiber Services, Inc. Refiner disc with curved refiner bars
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
WO1998055611A1 (fr) * 1997-06-06 1998-12-10 Regents Of The University Of Michigan Element de reponse a la neureguline et ses utilisations
NZ528767A (en) 1998-03-30 2005-08-26 Northwest Biotherapeutics Inc Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
CN1163602C (zh) 1998-04-07 2004-08-25 科里克萨公司 结核杆菌抗原融合蛋白及其应用
US7078483B2 (en) 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
WO2000050620A2 (fr) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Endokine alpha humain et methodes d'utilisation
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
WO2000069898A2 (fr) 1999-05-14 2000-11-23 Arbor Vita Corporation Interactions moleculaires dans les reactions allergiques
ATE364689T1 (de) 1999-11-18 2007-07-15 Dendreon Corp Nukleinsäuren, welche für endotheliasen kodieren, endotheliasen, sowie deren verwendung
EP2210948A3 (fr) 1999-12-10 2010-10-06 Life Technologies Corporation Utilisation de sites à recombinaison multiples avec une spécificité unique de clonage recombinatoire
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
EP1294949A4 (fr) 2000-06-15 2004-08-25 Human Genome Sciences Inc Facteur de necrose tumorale humain delta et epsilon
WO2002002641A1 (fr) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b
EP1967205B1 (fr) 2000-08-30 2012-10-10 Pfizer Products Inc. Anti-IgE vaccins
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
CA2430039C (fr) 2000-11-28 2014-01-28 Medimmune, Inc. Procedes d'administration / de dosage d'anticorps anti-rsv destines a la prevention et au traitement
WO2002060919A2 (fr) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules a demi-vies longues, compositions et utilisations de celles-ci
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US7176300B2 (en) 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
US7541512B2 (en) 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
AU2002255995A1 (en) 2001-03-30 2002-10-15 Avigenics, Inc. Avian lysozyme promoter
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
FI116851B (fi) 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
DK1572874T3 (da) 2001-05-25 2013-12-16 Human Genome Sciences Inc Antistoffer, der immunospecifikt binder til TRAIL receptorer
GB0113552D0 (en) * 2001-06-05 2001-07-25 Secr Defence Vaccines
EP1404842A2 (fr) 2001-06-29 2004-04-07 Novartis AG Methode de criblage de perv et son utilisation
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US7550650B2 (en) 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
US7335761B2 (en) 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US20060084056A1 (en) 2002-02-13 2006-04-20 Nadia Harbeck Methods for selecting treatment regimens and predicting outcomes in cancer patients
US7135562B2 (en) 2002-03-14 2006-11-14 University Of Cincinnati Avian iFABP gene expression controlling region
AU2003226065B2 (en) 2002-04-12 2009-02-26 Ludwig Institute For Cancer Research, Ltd Recombinant anti-interleukin-9 antibodies
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
WO2004058147A2 (fr) 2002-12-16 2004-07-15 Halozyme, Inc. Glycoproteine de chondroitinase (chasegp) humaine, son procede de preparation et compositions pharmaceutiques comprenant ladite glycoproteine
CA2512729C (fr) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
US8021833B2 (en) 2003-02-12 2011-09-20 Functional Genetics, Inc. Method for reducing HIV viral budding by administering a VPS28-specfic antibody that disrupts Gag-TSG101-VPS28 binding interactions
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
DK2177620T3 (en) 2003-03-05 2015-01-26 Halozyme Inc Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, use and pharmaceutical compositions comprising thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1613273B1 (fr) 2003-04-11 2012-06-13 MedImmune, LLC Anticorps il-9 recombinants et leurs utilisations
WO2004113498A2 (fr) 2003-06-13 2004-12-29 University Of Medicine And Dentistry Of New Jersey Arn interferases et leurs procedes d'utilisation
CA2532250A1 (fr) 2003-07-15 2005-02-03 Barros Research Institute Antigene eimeria tenella utilise dans l'immunotherapie de la coccidiose
US20050221383A1 (en) 2003-08-08 2005-10-06 Choong-Chin Liew Osteoarthritis biomarkers and uses thereof
AU2004286198C1 (en) 2003-08-18 2011-02-24 Medimmune, Llc Humanization of antibodies
WO2005032572A2 (fr) 2003-10-03 2005-04-14 Vib Vzw Moyens et procedes de recrutement et d'identification de celles souches
US20050227251A1 (en) 2003-10-23 2005-10-13 Robert Darnell Method of purifying RNA binding protein-RNA complexes
CA2543954C (fr) 2003-10-27 2016-11-08 Rosetta Inpharmatics Llc Procede pour designer des arnsi pour l'extinction de genes
HUE064610T2 (hu) 2003-12-23 2024-04-28 Genentech Inc Új anti-IL 13 antitestek és alkalmazásaik
WO2005097184A2 (fr) 2004-03-26 2005-10-20 Human Genome Sciences, Inc. Anticorps contre le recepteur nogo
CN101426489A (zh) 2004-04-16 2009-05-06 曹义海 抑制血管生成的成分和方法
EP1747292B1 (fr) 2004-05-07 2015-07-08 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methodes de diagnostic ou de traitement du cancer de la prostate au moyen du gene erg, seul ou combine a d'autres genes surexprimes ou sous-exprimes dans le cancer de la prostate
WO2006046994A2 (fr) 2004-07-30 2006-05-04 Mount Sinai School Of Medicine Of New York University Formes alternatives d'epissure de klf6 et polymorphisme d'adn de klf6 de cellules germinales associes a un risque accru de cancer
WO2006047639A2 (fr) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation d'une specificite d'anticorps par adaptation sur mesure de son affinite a un antigene apparente
WO2006055635A2 (fr) 2004-11-15 2006-05-26 Mount Sinai School Of Medicine Of New York University Compositions et methodes de modification de la signalisation autocrine wnt
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
NZ556158A (en) 2004-12-22 2010-04-30 Auckland Uniservices Ltd Trefoil factors and methods of treating proliferation disorders using same
JP5139083B2 (ja) 2005-01-25 2013-02-06 プロレキシーズ ファーマシューティカルズ インコーポレイテッド 抗腫瘍剤としてのキノキサリン誘導体
EP2520669A3 (fr) 2005-02-07 2013-02-27 GeneNews Inc. Biomarqueurs de l'ostéoarthrite douce et leurs utilisations
CA2602035C (fr) 2005-03-18 2015-06-16 Medimmune, Inc. Rearrangement de l'infrastructure d'anticorps
US9889197B2 (en) 2005-04-15 2018-02-13 Macrogenics, Inc. Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin
ES2971647T3 (es) 2005-04-15 2024-06-06 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
WO2006125141A2 (fr) 2005-05-17 2006-11-23 Amicus Therapeutics, Inc. Methode pour traiter la maladie de pompe au moyen de 1-desoxynojirimycine et de ses derives
WO2007005898A2 (fr) 2005-07-05 2007-01-11 Cornell Research Foundation, Inc. Blocage de l'emigration des leucocytes et de l'inflammation par le blocage de cd99l2
DK1919503T3 (en) 2005-08-10 2014-12-15 Macrogenics Inc Identification and preparation of antibodies with variant fc regions and methods of use thereof
TW200730825A (en) 2005-10-21 2007-08-16 Genenews Inc Method and apparatus for correlating levels of biomarker products with disease
CA2903896A1 (fr) 2005-11-04 2007-05-18 Genentech, Inc. Utilisation d'inhibiteurs de la voie du complement pour traiter des maladies oculaires
EP2387995A1 (fr) 2006-03-30 2011-11-23 PTC Therapeutics, Inc. Procédés pour la production d'une protéine fonctionnelle à partir d'ADN ayant une mutation non-sens et traitement de troubles associés
HUE030269T2 (en) 2006-06-26 2017-04-28 Macrogenics Inc FC RIIB-specific antibodies and methods for their use
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
KR101374983B1 (ko) 2006-08-28 2014-03-17 라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지 길항성 인간 ｌｉｇｈｔ-특이적 인간 모노클로날 항체를 포함하는 제약 조성물
US8541169B2 (en) 2006-10-10 2013-09-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alternations in ERG gene expression and detection and treatment methods based on those alterations
WO2008048545A2 (fr) 2006-10-16 2008-04-24 Medimmune, Llc. Molécules ayant des demi-vies réduites, compositions et leurs utilisations
MX2009005026A (es) 2006-11-15 2009-07-31 Functional Genetics Inc Anticuerpos anti-tsg101 y sus usos para tratamiento de infecciones virales.
TWI419904B (zh) 2006-12-18 2013-12-21 Genentech Inc 拮抗劑抗-ｎｏｔｃｈ３抗體及其用於預防及治療ｎｏｔｃｈ３相關疾病之用途
US8664364B2 (en) 2007-01-24 2014-03-04 Carnegie Mellon University Optical biosensors
MX2009013816A (es) 2007-06-21 2010-02-24 Macrogenics Inc Diacuerpos covalentes y usos de los mismos.
CA2691166A1 (fr) 2007-06-27 2008-12-31 Liu Dongxu Polypeptides et polynucleotides pour l'artemine et les ligands apparentes, et leurs procedes d'utilisation
LT2195023T (lt) 2007-08-29 2018-06-25 Sanofi Humanizuoti anti-cxcr5 antikūnai, jų dariniai ir jų panaudojimas
WO2009123894A2 (fr) 2008-04-02 2009-10-08 Macrogenics, Inc. Anticorps spécifiques de her2/neu et procédés d’utilisation de ceux-ci
EP2252631B1 (fr) 2008-04-02 2016-04-13 MacroGenics, Inc. Anticorps spécifiques du complexe bcr et procédés pour les utiliser
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
CA2726845C (fr) 2008-06-04 2017-09-26 Macrogenics, Inc. Anticorps a liaison alteree a fcrn et leurs procedes d'utilisation
KR101432474B1 (ko) 2008-09-07 2014-08-21 글라이코넥스 인코포레이티드 항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도
WO2010036978A2 (fr) 2008-09-25 2010-04-01 Transgenrx, Inc. Nouveaux vecteurs pour la production d'hormone de croissance
WO2010036976A2 (fr) 2008-09-25 2010-04-01 Transgenrx, Inc. Nouveaux vecteurs pour la production d'anticorps
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディ及びその使用
EP2367564A1 (fr) 2008-12-22 2011-09-28 Universität Regensburg Utilisation de la protéine norrin dans le traitement de maladies associées à une augmentation de l'activité de tgf-bêta
WO2010096388A2 (fr) 2009-02-18 2010-08-26 Carnegie Mellon University Colorants dendrimères désactivés pour détection de brillant
WO2010118360A1 (fr) 2009-04-09 2010-10-14 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Production de protéines au moyen de vecteurs à base de transposon
EP2424978B1 (fr) 2009-04-27 2018-08-15 Ottawa Hospital Research Institute Compositions et méthodes permettant de moduler les cellules souches et leurs utilisations
WO2010141329A1 (fr) 2009-06-01 2010-12-09 Medimmune, Llc Molecules a demi-vie prolongee et utilisations associees
DK2464664T3 (da) 2009-08-13 2016-01-18 Crucell Holland Bv Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
WO2011035205A2 (fr) 2009-09-18 2011-03-24 Calmune Corporation Anticorps dirigés contre candida, leurs collectes et procédés d'utilisation
WO2011046457A1 (fr) 2009-10-16 2011-04-21 Auckland Uniservices Limited Utilisations antinéoplasiques d'antagonistes d'artémine
WO2011057188A1 (fr) 2009-11-06 2011-05-12 Idexx Laboratories, Inc. Anticorps anti-cd20 canins
US9597346B2 (en) 2010-01-15 2017-03-21 Cornell University Methods for reducing protein levels in a cell
EP2577309B1 (fr) 2010-05-25 2016-11-23 Carnegie Mellon University Sondes ciblées de physiologie cellulaire
NZ703035A (en) 2010-07-09 2016-06-24 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
EP2659271A4 (fr) 2010-12-27 2015-04-08 Univ Brown Méthodes thérapeutiques et diagnostiques impliquant le biglycane et l'utrophine
WO2012162068A2 (fr) 2011-05-21 2012-11-29 Macrogenics, Inc. Domaines de liaison du sérum déimmunisé et leur utilisation pour prolonger la demi-vie du sérum
ES2690305T3 (es) 2011-09-16 2018-11-20 Ottawa Hospital Research Institute Composiciones de Wnt7a y métodos de utilización de las mismas
TWI605061B (zh) 2012-02-15 2017-11-11 諾佛 儂迪克股份有限公司 會結合及阻斷表現在骨髓細胞上觸發受體－１（ｔｒｅｍ－１）之抗體
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
JP6400480B2 (ja) 2012-02-15 2018-10-03 ノヴォ ノルディスク アー／エス ペプチドグリカン認識タンパク質１に結合する抗体
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
CA2877441A1 (fr) 2012-07-02 2014-01-09 Medizinische Universitat Wien Produit de separation du complement c4d pour le traitement d'affections inflammatoires
WO2014120975A1 (fr) 2013-02-01 2014-08-07 California Institute Of Technology Immunocontraception à médiation par un anticorps
EP3110974A4 (fr) 2014-02-24 2018-01-24 Celgene Corporation Méthodes d'utilisation d'un activateur du céréblon pour l'expansion de cellules neurales et le traitement de troubles du système nerveux central
JP6832709B2 (ja) 2014-05-16 2021-02-24 メディミューン，エルエルシー 新生児Ｆｃ受容体結合が改変されて治療および診断特性が強化された分子
US9458464B2 (en) 2014-06-23 2016-10-04 The Johns Hopkins University Treatment of neuropathic pain
KR102641268B1 (ko) 2014-07-17 2024-02-27 노보 노르디스크 에이/에스 점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발
US10434177B2 (en) 2014-11-17 2019-10-08 Carnegie Mellon University Activatable two-component photosensitizers
WO2016191418A1 (fr) 2015-05-26 2016-12-01 Salk Institute For Biological Studies Vecteurs d'expression spécifiques de motoneurones
US20190145961A1 (en) 2016-04-20 2019-05-16 Washington University Ppar agonist or lxr agonist for use in the treatment of systemic lupus erythematosus by modulation of lap activity
KR20200139219A (ko) 2018-04-02 2020-12-11 브리스톨-마이어스 스큅 컴퍼니 항-trem-1 항체 및 이의 용도
KR20230135586A (ko) 2021-01-24 2023-09-25 마이클 데이비드 포레스트 Atp 합성효소 억제제 - 미용 및 치료 용도
WO2023131901A1 (fr) 2022-01-07 2023-07-13 Johnson & Johnson Enterprise Innovation Inc. Matériaux et procédés de protéines de liaison à il-1beta
WO2024013727A1 (fr) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Matériau et procédés d'appariement amélioré par génie biologique de régions variables de liaison à l'antigène

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
EP0556197A4 (en) * 1990-09-25 1994-05-18 Univ Connecticut Prolonging expression of polynucleotides introduced into a cell
WO1992019749A1 (fr) * 1991-05-03 1992-11-12 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Apport cible de genes codant des recepteurs de surface cellulaire

Also Published As

Publication number Publication date
ES2154637T3 (es) 2001-04-16
AU668870B2 (en) 1996-05-23
JPH06510524A (ja) 1994-11-24
EP0584279A1 (fr) 1994-03-02
WO1992020316A3 (fr) 1993-01-21
EP0584279B1 (fr) 2001-03-14
DK0584279T3 (da) 2001-06-11
ATE199647T1 (de) 2001-03-15
AU2155092A (en) 1992-12-30
DE69231736T2 (de) 2001-10-25
DE69231736D1 (de) 2001-04-19
WO1992020316A2 (fr) 1992-11-26

Similar Documents

Publication Publication Date Title
AU668870B2 (en) Targeted delivery of genes encoding immunogenic proteins
EP0031812B1 (fr) Ameliorations se rapportant aux preparations immunologiques
EP0154902B2 (fr) Peptides codés par le gène pré-S de l'hépatite B et immunogènes et vaccines les contenant
KR900006574B1 (ko) 프리(pre)-S 유전자 코우드된 펩티드, B형 간염면역원, 왁찐, 진단법 및 합성지질소낭 담체
US4879225A (en) Enhanced production of antibodies utilizing insolubilized immune complexes
AU623106B2 (en) Diagnostic system
WO1996040731A1 (fr) Proteines modifiees conjuguees a du polyethylene-glycol (peg)
JP2633807B2 (ja) 抗イデイオタイプ抗体を産生するイモータルリンパ球
JP2005511047A (ja) 潜伏期膜タンパク質に対する抗体およびそれらの使用
CA2347411A1 (fr) Particules assimilees a des virus pour l'induction d'anticorps
US6656481B1 (en) Vaccinal preparations
US5084396A (en) Enhanced production of antibodies utilizing insolubilized immune complexes
Fiume et al. Inhibition of woodchuck hepatitis virus replication by adenine arabinoside monophosphate coupled to lactosaminated poly-L-lysine and administered by intramuscular route
Marusić-Galesić et al. Cellular immune response to the antigen administered as an immune complex in vivo.
US20040005321A1 (en) Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotheraphy
JP2003517021A (ja) 抗原送達
JPH07507207A (ja) ルイスｙ−特異的モノクローナル抗体ｂｒ５５−２に対する抗イディオタイプモノクローナル抗体およびその使用
Brumeanu et al. Derivatization with monomethoxypolyethylene glycol of Igs expressing viral epitopes obviates adjuvant requirements.
US6964843B1 (en) Methods and reagents for the detection of antibodies to adenovirus
CN110101867B (zh) 一种peg修饰的基于叶酸受体和巨胞饮的双功能抗肿瘤重组蛋白偶联物
JP2001517447A (ja) Ｂ型肝炎ウイルスポリペプチド
CA2074512A1 (fr) Medicaments et methodes de traitement du syndrome d'immuno-deficience acquise (sida) et du para-sida (arc) a l'aide d'anticorps antiglucides et d'antigenes glucidiques carbone
Yu et al. Induction of High Levels of Epitope‐Specific Antibodies by Epitope/Peptide Candidate Vaccines against Human Immunodeficiency Virus Type‐1 (HIV‐1)
EP0370090A1 (fr) Immunogenes et peptides biologiquement actifs derives de sequences partagees d'antigenes et d'anticorps anti-idiotypiques ou d'anticorps specifiques contre des recepteurs cellulaires des antigenes.
KR100359236B1 (ko) 면역 효과가 우수한 백신 조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued